Home » Market News » DirectorsTalk Highlights » AI-based initiatives catalyzing immunotherapy in 2018
Frontier IP Group Plc

AI-based initiatives catalyzing immunotherapy in 2018

Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of immunotherapy research.

Evotec investment in Exscientia:

With the ongoing successful collaboration between German-based biotech company Evotec and UK-based AI company Exscientia since early 2016, Evotec announced on September 28, 2017, a €15 million investment in Exscientia to acquire its minority stake. These two companies are aiming to generate new small molecule immuno-oncology drugs using their automated design platform.

Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.